The overall objective of the Core is to provide resources and expertise to perform and analyze data from gene expression, miRNA expression, ChIP-seq, and microbiota profiling assays that identify disease-specific transcriptional patterns and shifts in microbiota abundance in tissue of patients with IBD. Additionally, the Core will enable project investigators to perform functional validation in patient- derived organoid experimental systems to substantiate and guide their hypotheses obtained in patient samples and animal models. This will be facilitated through access to human samples from well- characterized adult and pediatric IBD patients and controls.
The inflammatory bowel diseases (IBD), primarily Crohn?s disease and ulcerative colitis, are highly heterogeneous in their presentation, progression, and response to treatment. The Human Tissue and Genomics Core aims to provide valuable tissue material, clinical history, and access to cutting edge genomics technologies in order to facilitate the discovery of biomarkers and biological mechanisms of distinct disease phenotypes within IBD.
Showing the most recent 10 out of 35 publications